ارزیابی تأثیرات خدمات بهداشتی در اثر تغییر از برند به ونلافاکسین عمومی در نیوزیلند تحت شرایط بی عدالتی قیمت

Although both products remain fully subsidized and available, there is little incentive for prescribers, pharmacists, or patients to switch to the less expensive generic brand. If savings to the national New Zealand budget are to be realized, additional policy measures should be implemented to minimize incentives for multiple and reverse switching, and prescribers, as key opinion leaders, could take the lead in promoting generics to their patients.